Nathan Nagel

Nathan is a medical and life-science entrepreneur with 24 years of experience. Nathan created and has led an online global oncology network for 15 years. READ MORE

Dr. Tony Williams, MA, MB, BS, FRCP

Dr Williams is an experienced drug developer with experience of large pharma and, this century, smaller start-ups, in the areas of early-stage development in oncology. READ MORE

Dr. CheeGee See, PHD

Dr. See has 30 years of industry experience in big pharma (GSK, Roche) and SME biotechs (Proteome Sciences, Global Gene Corp, Trajecture) with an excellent working network of C-level decision-makers. READ MORE

Dr. Asawari (Asa) Bapat (MD(DPB), PGDHHM, CABP(H))

Asawari (Asa) is a Medical Doctor with specialization in Clinical pathology, (Transfusion, Transplants, Lab Medicine and Immunology). She has 20+ years of Leadership experience as Medical Director, PI & Vice-President, managing & supervising, Complex Diagnostic Labs, Facilities for Regenerative Medicine, Gene & Cell Therapy Companies, Designing successful Clinical Trials towards success. READ MORE

Dr. Claire Oliver-Harwood, PhD

Dr Oliver-Harwood is the Pharma and Biotech Industry Liaison for OCS. Claire’s role is to facilitate communication and collaboration within the team and with customers to ensure smooth and efficient operations. Her background includes working in the CME and innovation space at Fratrem Group Ltd. and she gained R&D expertise in analytical roles at Pfizer, Zeneca Agrochemicals, Elan Drug Delivery, and Boots Healthcare International. Claire holds a first-class honours degree in Chemistry and a PhD in Organic Chemistry.

Dr. Nick Plowman, MD, FRCP, FRCR

Dr Nick PlowmanDr Nick Plowman is a consultant clinical oncologist and the Head of Clinical Oncology (Cancer Medicine and Radiation Therapy) at St Bartholomew’s Hospital, London and Hospital for Sick Children in London for thirty years. Dr Plowman is an authority on the optimal management of cancer and leads one of the country’s foremost teams tackling all cancers. He was trained and qualified at Cambridge University, and works globally with experience in the UK, EU, USA, and the Middle East. He is one of the country’s most experienced cancer physicians and, with his clinical team, has introduced new medical therapies, which are now standard practice. During his career, he has introduced aromatase inhibitors into breast cancer treatment (the most important innovation in breast cancer in the last forty years) and introduced adrenosuppresive glucocorticoid therapy into advanced prostate cancer (now best standard practice worldwide). He has also introduced radiation techniques that have been initially pioneering and later best standard practice. In his career he has changed best standard management in breast cancer, prostate cancer, ano-rectal cancer (aromatase inhibitors, adrenosuppression, and chemoradiotherapy respectively). His current interests include radiation therapy developments (new focal and proton beam) and modern genomics.